Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the company’s EP262 development program at the American Academy of Allergy, Asthma and Immunology Annual meeting being held in San Antonio, TX, February 24-27, 2023.
EP262 is a potent, highly selective antagonist of MRGPRX2 which inhibits agonist-induced mast cell degranulation and represents a novel potential treatment for a broad range of mast cell-mediated disorders. The presentation highlights preclinical data demonstrating that EP262 potently inhibits MRGPRX2-mediated degranulation of human mast cells and inhibits mast cell degranulation-induced vascular permeability in proprietary humanized MRGPRX2 transgenic mice
